In a clinical trial of patients with post-thrombotic syndrome, stent patency rates were comparable with or without add-on aspirin.
Post-thrombotic syndrome (PTS), manifested by chronic pain, discoloration, and leg swelling, is a common occurrence for patients with proximal deep vein thrombosis and may impact quality of life. Endovascular recanalization of chronically occluded femoral or iliac veins or the inferior vena cava has been attempted to improve symptoms in PTS. However, the optimal antithrombotic regimen post-stenting remains unknown.
In an industry-funded, multicenter, randomized trial, the investigators assigned patients in a 1:1 ratio to low-dose aspirin plus rivaroxaban (20 mg once daily) or rivaroxaban monotherapy (NCT04128956). The trial was terminated prematurely owing to slow recruitment after enrollment of 169 patients. The incidence of the primary eff…
Reviewing Author
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis